Inhibitor Therapeutics Inc (INTI)

[Golden Cross]

I am also, Yesterday surprised me also..$INTI

[makinezmoney]

$INTI: Look at $TRIL... $INTI looks the same


As the early goings of $TRIL


And now you see $TRIL from $0.27 to $3.42 in just 8wks.


This is whats about to happen to $INTI


GO $INTI

[makinezmoney]

$INTI: Competing head-on with $CLVS Clovis-Oncology


And thats trading at $9/sh


This is the best value in the Prostate Cancer oncology space right now.


$0.075 a steal.





GO $INTI

[makinezmoney]

$INTI: That would be me........


Unless there is someone else that I don't know of.


If so....... wherever you are, whether here or outside of iHUB....



Enjoy these cheapies



GO $INTI

[81vette]

INTI is being accumulated on my indicator

[81vette]

since nov 13th,nothing but higher lows,great chart

[MWM]

I'll sit on it for a little while. Let's see what happens! Phase 2 is advanced!

[makinezmoney]

$INTI: Sellers are selling to me


I'll buy it.


Works for me




GO $INTI

[81vette]

should get found soon,word is spreading also

[eageleye]

Agreed. A little surprised more people aren't on this.

[MWM]

Clear out a few sellers and Blue Skies come with ease imo...

[YeahYeah7]

Same Here, lets see where this goes today.

[Golden Cross]

Looking for INTI to get moving here

[MWM]

Looks like just the Beginning!

[makinezmoney]

$INTI: EXDI had a similar pattern just before


It ripped hard last year.



Must pay attention to these technicals.


Looks great here and well supported.


No sellers.


GO $INTI

[makinezmoney]

$INTI: Buying these dips again.


No brainer here



Mayne Pharma got this.......... we're Solid


GO $INTI

[MWM]

Day 2 Move, way too cheap here!

[81vette]

7 day chart,day 1 is a beauty,see day 2 today

[swimmer100]

https://www.prnewswire.com/news-releases/inhibitor-therapeutics-receives-prostate-cancer-ind-clearance-from-fda-300990980.html

[makinezmoney]

$INTI: Can't dispute Mayne-Pharms growth in US


And more production facility.

They definitely have the wherewithall..........

GO $INTI

[MWM]

Sellers above .10 but not below. Odd! One big buyer and we head to .50 imo!

[makinezmoney]

$INTI: Bought another 25k


Thank you Market Gods.



GO $INTI

[makinezmoney]

$INTI: Consolidate.... That was Leg #1


2 More legs to go.............. Wavessssssssssssss



Bull-flag signal waving Strong & Proud here.



Now at $0.092


Next flagpole gets us to $0.25


GO $INTI

[81vette]

have we found a golden goose,worth a chance down here

[makinezmoney]

$INTI: Clovis is $9/sh


$INTI in the same space........... at a fraction of the cost.


Relative to Peers....... super cheap here at $0.10



https://finance.yahoo.com/news/clovis-oncology-rubraca-rucaparib-granted-130000221.html




GO $INTI

[makinezmoney]

$INTI: From Humble Beginnings.........


And Foresight....... are Fortunes MADE.



Trust me... I know a thing or two :)



GO $INTI

[81vette]

payment 9% of future sales means they believe and stock is going up,not diluted to death

[makinezmoney]

$INTI: Mayne Pharma wanna make an M&A Deal


You know they will.......... they've done it before.










GO $INTI

[makinezmoney]

$INTI: Standard boilerplate Risk vs Oppty language


Scared money... make no MONEY.


Sell to me Sellers.


You have a Dedicated buyer here.



GO $INTI

[bababooyah]

2. Liquidity and management’s plans:

The Company had cash and cash equivalents of approximately $1.4 million as of September 30, 2019. Based on the Company’s current operational plan and budget, the Company expects that it has sufficient cash to manage its business into the third quarter of 2020, although this estimation assumes the Company does not begin any clinical trials, acquire options or rights to additional drug development opportunities or otherwise face unexpected events, costs or contingencies, any of which could affect the Company’s cash requirements. Available resources may be consumed more rapidly than anticipated, potentially resulting in the need for additional funding. Although named as only a nominal defendant in the civil action discussed in Note 5, the Company will have a role due to its technical connection with the matter in dispute. Extended legal proceedings could drain valuable time and resources away from the Company’s clinical and pre-clinical programs and may also impede any future efforts to raise additional capital.

The Company intends to finance additional research and development, commercialization and distribution efforts and its working capital needs primarily through:


•

proceeds from public and private financings (including, most recently, financing from our majority shareholder, Mayne Pharma) and, potentially, from other strategic transactions;


•

royalty revenue from Mayne Pharma from sales in the U.S. (if any) of SUBA-Itraconazole BCCNS upon and assuming approval by FDA (after earned royalties have been applied to any advances due under Third Amended SLA);


•

proceeds from the exercise of outstanding warrants previously issued in private financings to investors (including, potentially, warrants held by our majority shareholder, Mayne Pharma);


•

potential partnerships with other pharmaceutical companies to assist in the supply, manufacturing and distribution of our products for which we would expect to receive upfront milestone and royalty payments;


•

potential licensing and joint venture arrangements with third parties, including other pharmaceutical companies where we would receive funding based on out-licensing our product; and


•

government or private foundation grants or loans which would be awarded to us to further develop our current and future anti-cancer therapies.

However, there is a risk that none of these plans will be implemented in a manner necessary to sustain the Company for an extended period of time and that the Company will be unable to obtain additional financing when needed on commercially reasonable terms, if at all. If adequate funds are not available when needed, the Company may be required to significantly reduce or refocus operations or to obtain funds through arrangements that may require the Company to relinquish rights to technologies or potential markets, any of which could have a material adverse effect on the Company, its viability, its financial condition and its results of operations beyond the third quarter of 2020. In addition, a lack of adequate funds may force the Company to cease operations.

As a result of the foregoing circumstances, there is substantial doubt about our ability to continue as a going concern. The consolidated financial statements included herein do not include any adjustments relating to the recoverability or classification of asset carrying amounts or the amounts and classification of liabilities that may result should we be unable to continue as a going concern.

[makinezmoney]

$INTI: You'll make it on $DEAC


Then you'll take advantage of what you can here as well.


We gotta fund our future winners right and redeploy profits where needed.


Thats how you make....... EZ Money !


GO $INTI

[makinezmoney]

$INTI: Mayne-Pharma looking positively at $INTI now


This FDA-IND clearance on Suba...... well, it helps out there interest as well.


With the cash on hand that Mayne has.. and the other acquisitions that
they've made, won't shock me if they increase their stake in $INTI
or just buy them outright.


Mayne won't see this $0.088 prices on the Open Market for much longer
given these developments.


Ride the Whales.



GO $INTI

[MWM]

I blew my wad but I locked in 160K

[makinezmoney]

$INTI: Any sellers out there... sell to me


I'm buying.

Make your life easy.


No need to worry.


Gimme your shares.


Your trash... My Treasure.



I've been down this road before.


GO $INTI

[MWM]

Share Structure
Market Cap Market Cap
21,115,433
01/21/2020
Authorized Shares
500,000,000
01/16/2020
Outstanding Shares
370,446,185
01/16/2020
Restricted
Not Available
Unrestricted
Not Available
Held at DTC
13,646,149
01/16/2020

Float 77,847,90 201/15/2019

[makinezmoney]

$INTI: Sell them to me......... 300k and counting :)


Non-DILUTIVE finacier backstopped by Mayne Pharma.



3000 to 5000 here or there doesn't mean nothing.


The fun has just begun.



GO $INTI

[MWM]

This is crazy cheap! Money will find this! worth 100K share lotto for sure!

[makinezmoney]

$INTI: Mayne-Pharma $5Million Non-DILUTIVE Financing



Who's the blowhard that said here that the company is dumping shares ?


You have NO CLUE !





GO $INTI

[bababooyah]

Sellers lining up to sell low priced shares. Be careful.

[81vette]

macd rising,crossing to bull,been 2years,great sign

[makinezmoney]

$INTI: Prostate cancer only 1 Track


There's 3 others they haven't even highlighted yet on todays news.

Just look at those numbers.


And this thing is still only valued at $0.088


You have no idea how cheap this is relative to Peers

Going back over $0.15 shorty.... count on it.





GO $INTI

[makinezmoney]

$INTI: Bull-flag formation.


Only way but up here.


The tape doesn't lie.



Excellent accumulation opportunity here at $0.0888




GO $INTI

[81vette]

news keeps coming,30min ago was market watch update,keep em coming,could run big!!!

[makinezmoney]

$INTI: Mayne Pharma backstopping the funding.


Means........ no dilution necessary.


No Offering necessary.


Mayne has vested interest in the success of Inhibitor/Hedgepath.

Along with these royalties... they are providing commercialization after all.


Todays value totally undervalues Inhibitor relative to Peers.


You saw CLOVIS soar recently with FDA approval on something similar.


This is crazy undevalued here at $0.08 but people just don't understand
how undervalued.


Accumulation here is the Smart thing to do, while you still can.



GO $INTI

[MWM]

9% royalties in a massive Phase 2 drug with funding. This stock is very cheap imo!

[makinezmoney]

$INTI: Mayne Pharma majority ownership......... will buyout $INTI


Hence the majority stake in it.


And the readjustment from HEDGEpath.


Todays dev't along with Mayne involve renders this a very good value.


I don't mind if Mayne pays us $0.50/sh for our shares.


Accumulating here at $0.0888


https://www.maynepharma.com/media/2286/myx-2019-full-year-results-investor-presentation.pdf



GO $INTI

[MWM]

https://www.otcmarkets.com/stock/INTI/news/HedgePath-Pharmaceuticals-and-Mayne-Pharma-Enter-into-Updated-Collaboration-and-Funding-Agreements?id=213522

[81vette]

pullback expected,was overbought,now approaching oversold

[bababooyah]

The hype from the news will die down and the price per share will drift lower. Be careful.

[makinezmoney]

$INTI: No Secondary, No Dilution, Low Float, FDA-Clearance


Was $0.35 shares in 2018......... back to those levels after
coming from Highpath



Going higher from here.


Another $SAVA in the making


Not bad for an OTCQB stock... its not even PINK.


https://emerginggrowth.com/inhibitor-therapeutics-inc-otc-pink-inti-up-103-after-receiving-prostate-cancer-ind-clearance-from-fda/



Super steal here at $0.10



GO $INTI